

![]() |
Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy |
|
Authors | ||
Published in | Journal of Thrombosis and Haemostasis. 2013, vol. 11, no. 8, p. 1617-1619 | |
Keywords | ABO Blood-Group System/metabolism — Administration, Oral — Aged — Alleles — Case-Control Studies — Cytochrome P-450 CYP3A/metabolism — Female — Gene Frequency — Genetic Variation — Hormones/administration & dosage — Humans — Middle Aged — NF-E2-Related Factor 2/metabolism — Polymorphism, Single Nucleotide — Postmenopause — Pulmonary Embolism/blood — Regression Analysis — Risk Factors — Venous Thrombosis/blood — Washington | |
Identifiers | DOI: 10.1111/jth.12309 PMID: 23734777 | |
Full text | ||
Structures | ||
Research group | La maladie thromboembolique veineuse (808) | |
Citation (ISO format) | BLONDON, Marc et al. Lack of strong effect modification by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy. In: Journal of Thrombosis and Haemostasis, 2013, vol. 11, n° 8, p. 1617-1619. https://archive-ouverte.unige.ch/unige:89078 |